{
  "dot_image": [
    "Red.png"
  ],
  "References": [
    
  ],
  "Article": [
    {
      "header": "Primidone",
      "paragraph_US": [
        "Used to assess compliance, monitor appropriate  therapeutic level or assess toxicity."
      ],
      "paragraph_SI": [
        "Used to assess compliance, monitor appropriate  therapeutic level or assess toxicity."
      ]
    },
    {
      "header": "Reference Range",
      "paragraph_US": [
        "Therapeutic concentration: 9.0-12.5 µg/mL  \nToxic concentration: ≥15.0 µg/mL"
      ],
      "paragraph_SI": [
        "Therapeutic concentration 41.0-57.5 µmol/L  \nToxic concentration: ≥69.0 µmol/L"
      ]
    },
    {
      "header": "Interpretation",
      "paragraph_US": [
        "At steady-state, which is achieved  approximately 2 weeks after therapy is initiated, blood levels of primidone  that correlate with optimal response to the drug range from 9.0 µg/mL to 12.5  µg/mL for adults and 7.0 µg/mL to 10.0 µg/mL for children <5 years of  age."
      ],
      "paragraph_SI": [
        "At steady-state, which is achieved  approximately 2 weeks after therapy is initiated, blood levels of primidone  that correlate with optimal response to the drug range from 41.0 – 57.5  µmol/L for adults and 32.0 – 46.0 µmol/L for children <5 years of  age."
      ]
    },
    {
      "header": "Clinical  Information",
      "paragraph_US": [
        "Primidone is used for control of grand mal seizures that are refractory to  other antiepileptics and seizures of psychomotor or focal origin.     Primidone exhibits a volume of distribution of 0.6 L/kg and a half-life of 8  hours."
      ],
      "paragraph_SI": [
        "Primidone is used for control of grand mal seizures that are refractory to  other antiepileptics and seizures of psychomotor or focal origin.     Primidone exhibits a volume of distribution of 0.6 L/kg and a half-life of 8  hours."
      ]
    }
  ]
}